— Research monograph
RT3
The first triple GIP/GLP-1/glucagon receptor agonist to clear Phase 2 trials.
- Class
- Triple agonist at GIP, GLP-1, and glucagon receptors (synthetic peptide)
- Half-life (research)
- ~6 days (early clinical pharmacokinetic reports).
- Origin
- First publicly characterized by Coskun et al. in 2022 as the next-generation evolution of the dual-incretin concept embodied in TZ2.
- Solubility
- Reconstitutes in bacteriostatic water.
What is RT3?
RT3 is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation.
The compound is currently in late-stage clinical investigation for obesity and type 2 diabetes. Public literature is concentrated in Phase 1–2 trial reports and preclinical pharmacology.
How does RT3 work?
Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models.
Research applications
- Triple-incretin pharmacology
- Energy expenditure research
- Comparative incretin-agonist studies
- Metabolic flux models
Form & storage
RT3 ships as a sealed, lyophilized (freeze-dried) powder. Reconstitutes in bacteriostatic water. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.
Frequently asked questions
What is RT3?
RT3 is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation. Merit supplies it as a lyophilized research compound for research use only — not for human or veterinary use.
How does RT3 work?
Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of RT3?
~6 days (early clinical pharmacokinetic reports). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit RT3 for human use?
No. It is sold strictly for research use only — not for human or veterinary use, and not for diagnostic or therapeutic use. Every batch is tested before it is listed, and its certificate of analysis documenting ≥99% HPLC purity is published in the COA library.
References
- Coskun T, Urva S, Roell WC, et al. Cell Metabolism, 2022 · PMID 35985340
- Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine, 2023 · PMID 37366315
- Rosenstock J, Frias J, Jastreboff AM, et al. The Lancet, 2023 · PMID 37385280
For research use only. Not for human or veterinary use. Not FDA-approved. Reference information summarized from published literature — not medical or dosing advice.
— Keep reading